JOIN OUR COMMUNITY

Europe

View All
Germany goes to Bangalore: Formycon’s India deal is the latest sign that biosimilar manufacturing is moving east — permanently
July 21, 2026 Off

Germany goes to Bangalore: Formycon’s India deal is the latest sign that biosimilar manufacturing is moving east — permanently

By Dino Mustafić

A Munich-based biosimilar developer just signed a strategic manufacturing partnership with an Indian CDMO. According to industry analysts, it is not the first such deal, and it will not be...

How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again

How the Hormuz blockade became a prolonged war: pharma’s supply nightmare deepens as truce fails and strait closes again

July 21, 2026 Off
Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30

Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30

July 13, 2026 Off

USA

View All
Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
March 11, 2026 Off

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention

By Dino Mustafić

A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

February 26, 2026 Off
BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

July 29, 2025 Off

My Pharmaceutical

View All
Beyond the transplant list: the pediatric cardiomyopathy pipeline finally has momentum
August 4, 2026 0

Beyond the transplant list: the pediatric cardiomyopathy pipeline finally has momentum

By Dino Mustafić

Dilated cardiomyopathy (DCM) is the most common form of cardiomyopathy in children and the leading reason kids end up on a heart transplant list. For decades, when medical management failed, transplant was often the only option left. That's starting to...

BioCardia’s cell therapy may help the failing heart stop working against itself
March 13, 2026 Off

BioCardia’s cell therapy may help the failing heart stop working against itself

By Dino Mustafić

Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for...

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
March 11, 2026 Off

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention

By Dino Mustafić

A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according...




Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
July 13, 2026 Off

Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30

By Dino Mustafić

Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company’s RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table stakes for any trial — and more on what happens over the next six to eight weeks, since interim data is still on track for late summer.